We identify emerging fields of science and medicine where innovation can drive transformative change in areas of unmet medical need. Using both market insight and our health-equity lens, we prioritize opportunities — whether scientific, clinical, or digital — that have the potential to meaningfully improve outcomes across diverse patient populations.
Working with scientific founders and expert advisors, we conduct rigorous technical, clinical, and commercial diligence to validate each opportunity. Our team assesses mechanism, market, and pathway readiness while developing strategies to mitigate key risks before company formation.
We build, license, or acquire high-potential assets and assemble founding teams around them. Each venture is capitalized, structured, and supported through our shared Syridex infrastructure — positioned from day one to execute efficiently and scale responsibly.
As active partners, advisors, and board members, we work hand-in-hand with portfolio leadership to accelerate development, secure follow-on investment, and expand access to innovation. Our goal is to turn scientific and technological breakthroughs into sustainable, equitable health impact.
Every company we build is designed to make health innovation more human, more inclusive, and more equitable.
Antigenix is a preclinical oncology company developing next-generation antibody-drug conjugates (ADCs) to treat aggressive cancers, including triple-negative breast cancer — a disease with disproportionate impact among underserved populations.
Lead Indication: Triple Negative Breast Cancer
Modalities: Antibody drug conjugates
Qunova is a digital health company developing an AI-driven platform that enables organizations to model, simulate, and optimize population health strategies before implementation.
Several emerging technologies are progressing through our discovery and diligence pipeline as we evaluate the next company to launch under the Syridex Bio platform.
